<?xml version="1.0" ?>
<!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd">
<pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="brief-report">
  <?properties open_access?>
  <front>
    <journal-meta>
      <journal-id journal-id-type="nlm-ta">Cancer Chemother Pharmacol</journal-id>
      <journal-title-group>
        <journal-title>Cancer Chemotherapy and Pharmacology</journal-title>
      </journal-title-group>
      <issn pub-type="ppub">0344-5704</issn>
      <issn pub-type="epub">1432-0843</issn>
      <publisher>
        <publisher-name>Springer-Verlag</publisher-name>
        <publisher-loc>Berlin/Heidelberg</publisher-loc>
      </publisher>
    </journal-meta>
    <article-meta>
      <article-id pub-id-type="pmid">21681573</article-id>
      <article-id pub-id-type="pmc">3180562</article-id>
      <article-id pub-id-type="publisher-id">1691</article-id>
      <article-id pub-id-type="doi">10.1007/s00280-011-1691-z</article-id>
      <article-categories>
        <subj-group subj-group-type="heading">
          <subject>Short Communication</subject>
        </subj-group>
      </article-categories>
      <title-group>
        <article-title>Efficacy of increased-dose erlotinib for central nervous system metastases in non-small cell lung cancer patients with epidermal growth factor receptor mutation</article-title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author" corresp="yes">
          <name>
            <surname>Togashi</surname>
            <given-names>Yosuke</given-names>
          </name>
          <address>
            <phone>+81-75-751-3830</phone>
            <fax>+81-75-751-4643</fax>
            <email>ytogashi@kuhp.kyoto-u.ac.jp</email>
          </address>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Masago</surname>
            <given-names>Katsuhiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Fukudo</surname>
            <given-names>Masahide</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Tsuchido</surname>
            <given-names>Yasuhiro</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Okuda</surname>
            <given-names>Chiyuki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Kim</surname>
            <given-names>Young Hak</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Ikemi</surname>
            <given-names>Yasuaki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Sakamori</surname>
            <given-names>Yuichi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mio</surname>
            <given-names>Tadashi</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Katsura</surname>
            <given-names>Toshiya</given-names>
          </name>
          <xref ref-type="aff" rid="Aff2">2</xref>
        </contrib>
        <contrib contrib-type="author">
          <name>
            <surname>Mishima</surname>
            <given-names>Michiaki</given-names>
          </name>
          <xref ref-type="aff" rid="Aff1">1</xref>
        </contrib>
        <aff id="Aff1"><label>1</label>Department of Respiratory Medicine, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507 Japan </aff>
        <aff id="Aff2"><label>2</label>Department of Pharmacy, Graduate School of Medicine, Kyoto University, 54 Shogoin-Kawaracho, Sakyo-ku, Kyoto, 606-8507 Japan </aff>
      </contrib-group>
      <pub-date pub-type="epub">
        <day>17</day>
        <month>6</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="pmc-release">
        <day>17</day>
        <month>6</month>
        <year>2011</year>
      </pub-date>
      <pub-date pub-type="ppub">
        <month>10</month>
        <year>2011</year>
      </pub-date>
      <volume>68</volume>
      <issue>4</issue>
      <fpage>1089</fpage>
      <lpage>1092</lpage>
      <history>
        <date date-type="received">
          <day>20</day>
          <month>4</month>
          <year>2011</year>
        </date>
        <date date-type="accepted">
          <day>1</day>
          <month>6</month>
          <year>2011</year>
        </date>
      </history>
      <permissions>
        <copyright-statement>&#xA9; The Author(s) 2011</copyright-statement>
      </permissions>
      <abstract id="Abs1">
        <sec>
          <title>Purpose</title>
          <p>Recent reports indicate that refractory central nervous system (CNS) metastases of non-small cell lung cancer (NSCLC) are improved by high-dose gefitinib or erlotinib administration. We describe a Japanese woman with NSCLC and CNS metastases who was resistant to 75&#xA0;mg daily erlotinib, but the metastases were improved by 150&#xA0;mg daily erlotinib. We investigated the plasma and CSF concentrations of erlotinib at each dose as well as the correlation between the plasma and CSF concentrations of erlotinib.</p>
        </sec>
        <sec>
          <title>Methods</title>
          <p>Including this patient, we administered 150&#xA0;mg erlotinib daily to nine NSCLC patients with CNS metastases and measured the plasma and CSF concentrations just before administration on day 8. The concentrations were determined using high-performance liquid chromatography with ultraviolet detection.</p>
        </sec>
        <sec>
          <title>Results</title>
          <p>The plasma and CSF concentrations of erlotinib at a dose of 75&#xA0;mg were 433 and 14&#xA0;nM, respectively. The plasma and CSF concentrations of erlotinib at a dose of 150&#xA0;mg were increased to 1,117 and 44&#xA0;nM, respectively. The mean&#xA0;&#xB1;&#xA0;standard deviation of CSF concentrations and penetration rates were 106&#xA0;&#xB1;&#xA0;59&#xA0;nM and 4.5&#xA0;&#xB1;&#xA0;1.5%, respectively. There was a good correlation (<italic>R</italic><sup><italic>2</italic></sup>&#xA0;=&#xA0;0.84) between plasma and CSF concentrations (<italic>P</italic>&#xA0;=&#xA0;0.0005).</p>
        </sec>
        <sec>
          <title>Conclusions</title>
          <p>This study indicates that CSF concentrations of erlotinib depend on its plasma concentration. As seen in this patient, high CSF concentrations of erlotinib can be achieved by high-dose administration, and this finding suggests the efficacy of high-dose administration, especially to refractory CNS metastases of NSCLC patients.</p>
        </sec>
      </abstract>
      <kwd-group>
        <title>Keywords</title>
        <kwd>Non-small cell lung cancer</kwd>
        <kwd>Epidermal growth factor receptor</kwd>
        <kwd>Tyrosine kinase inhibitor</kwd>
        <kwd>Erlotinib</kwd>
        <kwd>Central nervous system metastasis</kwd>
        <kwd>Cerebrospinal fluid</kwd>
      </kwd-group>
      <custom-meta-group>
        <custom-meta>
          <meta-name>issue-copyright-statement</meta-name>
          <meta-value>&#xA9; Springer-Verlag 2011</meta-value>
        </custom-meta>
      </custom-meta-group>
    </article-meta>
  </front>
  <body>
    <sec id="Sec1">
      <title>Introduction</title>
      <p>Patients with non-small cell lung cancer (NSCLC) who have somatic activating mutations of the epidermal growth factor receptor (EGFR) gene (<italic>EGFR</italic> mutations) generally respond to EGFR-tyrosine kinase inhibitors (EGFR-TKIs, e.g., gefitinib and erlotinib) [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Nevertheless, the majority of these patients experience eventual disease progression, despite an initial dramatic response to treatment. The central nervous system (CNS) is a common site of recurrence, which is thought to be due to penetration of the agents into the CNS [<xref ref-type="bibr" rid="CR3">3</xref>, <xref ref-type="bibr" rid="CR4">4</xref>]. A previous report described refractory CNS metastases of NSCLC that were improved by high-dose gefitinib [<xref ref-type="bibr" rid="CR5">5</xref>]. Several cases in which CNS metastases resistant to gefitinib were improved by erlotinib have been also reported [<xref ref-type="bibr" rid="CR6">6</xref>]. In addition, in several articles, intermittent, high-dose erlotinib improved CNS metastases that were resistant to continuous, normal-dose erlotinib [<xref ref-type="bibr" rid="CR7">7</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>]. These challenges are based on the hypothesis that high cerebrospinal fluid (CSF) concentrations may be achieved by high-dose administration of EGFR-TKIs, with higher CSF concentrations achieved by erlotinib compared with gefitinib. We previously reported the CSF concentrations of erlotinib and its penetration rates in four NSCLC patients with CNS metastases [<xref ref-type="bibr" rid="CR10">10</xref>]. In this article, we describe a Japanese woman with NSCLC and <italic>EGFR</italic> mutation having CNS metastases that are resistant to 75&#xA0;mg daily erlotinib. The metastases were subsequently improved by 150&#xA0;mg daily erlotinib. We investigated the plasma and CSF concentrations of erlotinib at each dose. Furthermore, including previous data, we investigated the correlation between plasma and CSF concentrations.</p>
    </sec>
    <sec id="Sec2" sec-type="methods">
      <title>Patients and methods</title>
      <sec id="Sec3">
        <title>Patients</title>
        <p>A 66-year-old Japanese woman was diagnosed with advanced lung adenocarcinoma and <italic>EGFR</italic> mutation (L858R) 3&#xA0;years prior. Erlotinib had been administered as fourth line of treatment. Before the initiation of erlotinib, the patient had no CNS metastases. Although partial response (PR) was achieved, the erlotinib dose was reduced from 150 to 75&#xA0;mg daily due to grade 3 fatigue. After progression-free survival (PFS) of 12&#xA0;months, the patient experienced recurrent CNS metastases. The plasma and CSF concentrations of erlotinib just before administration of the 75-mg dose were 433 and 14&#xA0;nM, respectively. The patient received whole-brain radiotherapy (WBRT), but the CNS metastases did not improve (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>a). The dose was subsequently increased to 150&#xA0;mg daily; the plasma and CSF concentrations just before administration of erlotinib on day 8 erlotinib were 1,117 and 44&#xA0;nM, respectively. Four weeks after the initiation of 150&#xA0;mg administration of erlotinib, CNS metastases improved (Fig.&#xA0;<xref rid="Fig1" ref-type="fig">1</xref>b).<fig id="Fig1"><label>Fig.&#xA0;1</label><caption><p>Brain magnetic resonance imaging (MRI) in the 66-year-old Japanese female patient. <bold>a</bold> Brain MRI after whole-brain radiotherapy demonstrated stable brain metastases (<italic>arrowheads</italic>). At this point, 75&#xA0;mg daily erlotinib was administered. <bold>b</bold> Four weeks after initiation of 150&#xA0;mg daily erlotinib, the metastases were improved (<italic>arrowheads</italic>)</p></caption><graphic xlink:href="280_2011_1691_Fig1_HTML" id="MO1"/></fig></p>
        <p>We previously reported the plasma and CSF concentrations of four NSCLC patients with CNS metastases (cases 1&#x2013;4) [<xref ref-type="bibr" rid="CR10">10</xref>]. In addition to these patients, we investigated the plasma and CSF concentrations of four other NSCLC patients with CNS metastases (cases 5&#x2013;8) (Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table&#xA0;1</label><caption><p>Patient characteristics</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Cases</th><th align="left">Age (yr)</th><th align="left">Sex</th><th align="left">PS</th><th align="left">Histology</th><th align="left"><italic>EGFR</italic> gene</th><th align="left">Smoking status</th><th align="left">Previous chemotherapy regimen</th><th align="left">Previous gefitinib (length of PFS)</th><th align="left">Previous WBRT</th></tr></thead><tbody><tr><td align="left">1</td><td align="left">59</td><td align="left">F</td><td align="left">3</td><td align="left">Ad</td><td align="left">NE</td><td align="left">Never</td><td align="left">3</td><td align="left">Yes (10&#xA0;months)</td><td align="left">Yes</td></tr><tr><td align="left">2</td><td align="left">82</td><td align="left">F</td><td align="left">4</td><td align="left">Ad</td><td align="left">Wild type</td><td align="left">Never</td><td align="left">0</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">3</td><td align="left">70</td><td align="left">F</td><td align="left">3</td><td align="left">Ad</td><td align="left">Wild type</td><td align="left">Never</td><td align="left">1</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">4</td><td align="left">86</td><td align="left">F</td><td align="left">3</td><td align="left">Ad</td><td align="left">Ex 21; L858R</td><td align="left">Never</td><td align="left">1</td><td align="left">Yes (7&#xA0;months)</td><td align="left">No</td></tr><tr><td align="left">5</td><td align="left">67</td><td align="left">F</td><td align="left">1</td><td align="left">Ad</td><td align="left">Ex 21; L858R</td><td align="left">Never</td><td align="left">1</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">6</td><td align="left">72</td><td align="left">M</td><td align="left">0</td><td align="left">Ad</td><td align="left">Ex 21; L858R</td><td align="left">Former</td><td align="left">1</td><td align="left">No</td><td align="left">No</td></tr><tr><td align="left">7</td><td align="left">81</td><td align="left">M</td><td align="left">1</td><td align="left">Ad</td><td align="left">Ex 19 deletion</td><td align="left">Former</td><td align="left">1</td><td align="left">Yes (46&#xA0;months)</td><td align="left">Yes</td></tr><tr><td align="left">8</td><td align="left">85</td><td align="left">F</td><td align="left">2</td><td align="left">Ad</td><td align="left">Ex 21; L858R</td><td align="left">Never</td><td align="left">1</td><td align="left">No</td><td align="left">Yes</td></tr><tr><td align="left">&#xA0;<sup>a</sup></td><td align="left">66</td><td align="left">F</td><td align="left">1</td><td align="left">Ad</td><td align="left">Ex 21; L858R</td><td align="left">Never</td><td align="left">3</td><td align="left">No</td><td align="left">Yes</td></tr></tbody></table><table-wrap-foot><p><italic>PS</italic> performance status, <italic>EGFR</italic> epidermal growth factor receptor, <italic>PFS</italic> progression-free survival, <italic>WBRT</italic> whole-brain radiotherapy, <italic>F</italic> female, <italic>M</italic> male, <italic>Ad</italic> adenocarcinoma, <italic>NE</italic> not evaluated, <italic>Never</italic> never-smoker, <italic>Former</italic> former-smoker</p><p><sup>a</sup>A 66-year-old Japanese female patient in this study</p></table-wrap-foot></table-wrap></p>
      </sec>
      <sec id="Sec4" sec-type="materialsandmethods">
        <title>Methods</title>
        <p>Blood and CSF samples were obtained just before the administration of 150&#xA0;mg erlotinib on day 8 when steady-state plasma concentrations of erlotinib were assumed to be achieved. Plasma and CSF concentrations of erlotinib were determined using high-performance liquid chromatography with ultraviolet detection as previously reported [<xref ref-type="bibr" rid="CR11">11</xref>]. Before the collection of samples and analysis, we obtained written informed consent from all patients.</p>
      </sec>
      <sec id="Sec5">
        <title>Statistical analysis</title>
        <p>Linear regression was performed on the data in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref> by fitting a straight line. The <italic>R</italic><sup><italic>2</italic></sup> value was used to measure the strength of the relationship between the plasma and CSF concentrations of erlotinib. The 150-mg daily erlotinib data from this 66-year-old Japanese female patient were analyzed, and the 75-mg daily erlotinib data were excluded. Linear regression analysis, performed using JMP 8 software (SAS Institute, Cary, NC, USA), was two-tailed, and <italic>P</italic> values less than 0.05 were considered statistically significant.<fig id="Fig2"><label>Fig.&#xA0;2</label><caption><p>Correlation between plasma concentrations and cerebrospinal fluid (CSF) concentrations of erlotinib. A good correlation (<italic>R</italic><sup><italic>2</italic></sup>&#xA0;=&#xA0;0.84) was demonstrated (<italic>P</italic>&#xA0;=&#xA0;0.0005)</p></caption><graphic xlink:href="280_2011_1691_Fig2_HTML" id="MO2"/></fig></p>
      </sec>
    </sec>
    <sec id="Sec6">
      <title>Results</title>
      <p>The clinical characteristics of all patients (<italic>n</italic>&#xA0;=&#xA0;9) are summarized in Table&#xA0;<xref rid="Tab1" ref-type="table">1</xref>. In CNS lesions, 7 of the 9 patients achieved PR (78%) and 5 of the 6 patients with <italic>EGFR</italic> mutations achieved PR (83%). Gefitinib was administered to three patients prior to erlotinib therapy; these patients achieved PR but had CNS recurrence after a long PFS of more than 6&#xA0;months. Two of these three patients achieved PR after erlotinib therapy in spite of gefitinib resistance.</p>
      <p>The plasma and CSF concentrations are summarized in Table&#xA0;<xref rid="Tab2" ref-type="table">2</xref>. The mean&#xA0;&#xB1;&#xA0;standard deviation (SD) of CSF concentrations and penetration rates were 106&#xA0;&#xB1;&#xA0;59&#xA0;nM and 4.5&#xA0;&#xB1;&#xA0;1.5%, respectively. As seen in Fig.&#xA0;<xref rid="Fig2" ref-type="fig">2</xref>, there was a good correlation (<italic>R</italic><sup><italic>2</italic></sup>&#xA0;=&#xA0;0.84) between plasma and CSF concentrations (<italic>P</italic>&#xA0;=&#xA0;0.0005).<table-wrap id="Tab2"><label>Table&#xA0;2</label><caption><p>Plasma and cerebrospinal fluid concentrations of erlotinib, and central nervous system metastases response</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Case</th><th align="left">Plasma concentration (nM)</th><th align="left">CSF concentration (nM)</th><th align="left">Penetration rate (%)</th><th align="left">CNS response<sup>a</sup></th></tr></thead><tbody><tr><td align="left">1</td><td align="left">2,082</td><td align="left">98</td><td align="left">4.7</td><td align="left">Partial response</td></tr><tr><td align="left">2</td><td align="left">4,059</td><td align="left">202</td><td align="left">5.0</td><td align="left">Stable disease</td></tr><tr><td align="left">3</td><td align="left">4,922</td><td align="left">156</td><td align="left">3.2</td><td align="left">Partial response</td></tr><tr><td align="left">4</td><td align="left">544</td><td align="left">42</td><td align="left">7.7</td><td align="left">Stable disease</td></tr><tr><td align="left">5</td><td align="left">2,575</td><td align="left">98</td><td align="left">3.8</td><td align="left">Partial response</td></tr><tr><td align="left">6</td><td align="left">1,314</td><td align="left">47</td><td align="left">3.5</td><td align="left">Partial response</td></tr><tr><td align="left">7</td><td align="left">1,886</td><td align="left">98</td><td align="left">5.2</td><td align="left">Partial response</td></tr><tr><td align="left">8</td><td align="left">5,376</td><td align="left">172</td><td align="left">3.2</td><td align="left">Partial response</td></tr><tr><td align="left">(75&#xA0;mg erlotinib)<sup>b</sup></td><td align="left">433</td><td align="left">14</td><td align="left">3.3</td><td align="left">Progressive disease</td></tr><tr><td align="left">(150&#xA0;mg erlotinib)<sup>b</sup></td><td align="left">1,117</td><td align="left">44</td><td align="left">3.9</td><td align="left">Partial response</td></tr><tr><td align="left">Mean&#xA0;&#xB1;&#xA0;SD<sup>c</sup></td><td align="left">2,653&#xA0;&#xB1;&#xA0;1,734</td><td align="left">106&#xA0;&#xB1;&#xA0;59</td><td align="left">4.5&#xA0;&#xB1;&#xA0;1.5</td><td align="left"/></tr></tbody></table><table-wrap-foot><p><italic>CSF</italic> cerebrospinal fluid, <italic>CNS</italic> central nervous system, <italic>SD</italic> standard deviation</p><p><sup>a</sup>Responses were assessed by magnetic resonance imaging with use of the Response Evaluation Criteria in Solid Tumor version 1.1</p><p><sup>b</sup>A 66-year-old Japanese female patient in this study</p><p><sup>c</sup>We analyzed the mean&#xA0;&#xB1;&#xA0;SD from all data except for the data from the 66-year-old Japanese female patient at a dose of 75&#xA0;mg erlotinib</p></table-wrap-foot></table-wrap></p>
    </sec>
    <sec id="Sec7">
      <title>Discussion</title>
      <p>This study demonstrated that there is a good correlation (<italic>R</italic><sup><italic>2</italic></sup>&#xA0;=&#xA0;0.84) between plasma and CSF concentrations of erlotinib (<italic>P</italic>&#xA0;=&#xA0;0.0005), which indicates that high CSF concentrations can be achieved by high plasma concentrations. That is, high CSF concentrations can be achieved by high-dose erlotinib administration. CNS metastases of the 66-year-old Japanese female patient responded to 150&#xA0;mg daily erlotinib despite resistance to 75&#xA0;mg daily erlotinib, likely because of higher CSF concentrations. There are several reports based on the hypothesis that high CSF concentrations may be achieved by high-dose erlotinib administration [<xref ref-type="bibr" rid="CR5">5</xref>&#x2013;<xref ref-type="bibr" rid="CR9">9</xref>], and our study supports this hypothesis.</p>
      <p>The mean&#xA0;&#xB1;&#xA0;SD of CSF penetration rates were 4.5&#xA0;&#xB1;&#xA0;1.5%, and this result was similar to that of recent another study [<xref ref-type="bibr" rid="CR12">12</xref>]. However, the rates of our study were ranged from 3.2 to 7.7% and those of another study ranged from 2.5 to 13.3%, which indicates that there seem to be difference in the penetration rate between individuals. Recently, it has been reported that some transporters restrict brain penetration of erlotinib [<xref ref-type="bibr" rid="CR13">13</xref>, <xref ref-type="bibr" rid="CR14">14</xref>]. Polymorphisms of these transporters can be associated with this individual difference in the penetration rate.</p>
      <p>Since systemic chemotherapy is thought to play a limited role in CNS metastases because of the belief that the brain is a pharmacological sanctuary, patients with NSCLC who showed initial good responses to EGFR-TKIs often had recurrent CNS metastases. Considering CSF concentrations, high-dose EGFR-TKIs can be effective for such refractory metastases. Furthermore, the association between CNS responses/recurrence and CSF concentrations should be investigated in the future.</p>
    </sec>
  </body>
  <back>
    <ack>
      <title>Conflicts of interest</title>
      <p>We declare that we have no potential conflict of interest related to this article.</p>
      <p><bold>Open Access</bold> This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.</p>
    </ack>
    <ref-list id="Bib1">
      <title>References</title>
      <ref id="CR1">
        <label>1.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Paez</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>J&#xE4;nne</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Lee</surname>
              <given-names>JC</given-names>
            </name>
            <name>
              <surname>Tracy</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Greulich</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Gabriel</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Herman</surname>
              <given-names>P</given-names>
            </name>
            <name>
              <surname>Kaye</surname>
              <given-names>FJ</given-names>
            </name>
            <name>
              <surname>Lindeman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Boggon</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Naoki</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sasaki</surname>
              <given-names>H</given-names>
            </name>
            <name>
              <surname>Fujii</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Eck</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Sellers</surname>
              <given-names>WR</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>BE</given-names>
            </name>
            <name>
              <surname>Meyerson</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy</article-title>
          <source>Science</source>
          <year>2004</year>
          <volume>304</volume>
          <fpage>1497</fpage>
          <lpage>1500</lpage>
          <pub-id pub-id-type="doi">10.1126/science.1099314</pub-id>
          <pub-id pub-id-type="pmid">15118125</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR2">
        <label>2.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lynch</surname>
              <given-names>TJ</given-names>
            </name>
            <name>
              <surname>Bell</surname>
              <given-names>DW</given-names>
            </name>
            <name>
              <surname>Sordella</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Gurubhagavatula</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Okimoto</surname>
              <given-names>RA</given-names>
            </name>
            <name>
              <surname>Brannigan</surname>
              <given-names>BW</given-names>
            </name>
            <name>
              <surname>Harris</surname>
              <given-names>PL</given-names>
            </name>
            <name>
              <surname>Haserlat</surname>
              <given-names>SM</given-names>
            </name>
            <name>
              <surname>Supko</surname>
              <given-names>JG</given-names>
            </name>
            <name>
              <surname>Haluska</surname>
              <given-names>FG</given-names>
            </name>
            <name>
              <surname>Louis</surname>
              <given-names>DN</given-names>
            </name>
            <name>
              <surname>Christiani</surname>
              <given-names>DC</given-names>
            </name>
            <name>
              <surname>Settleman</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Haber</surname>
              <given-names>DA</given-names>
            </name>
          </person-group>
          <article-title>Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib</article-title>
          <source>N Engl J Med</source>
          <year>2004</year>
          <volume>350</volume>
          <fpage>2129</fpage>
          <lpage>2139</lpage>
          <pub-id pub-id-type="doi">10.1056/NEJMoa040938</pub-id>
          <pub-id pub-id-type="pmid">15118073</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR3">
        <label>3.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Omuro</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Kris</surname>
              <given-names>MG</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Franceschi</surname>
              <given-names>E</given-names>
            </name>
            <name>
              <surname>Shah</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Milton</surname>
              <given-names>DT</given-names>
            </name>
            <name>
              <surname>Abrey</surname>
              <given-names>LE</given-names>
            </name>
          </person-group>
          <article-title>High incidence of disease recurrence in the brain and leptomeninges in patients with nonsmall cell lung carcinoma after response to gefitinib</article-title>
          <source>Cancer</source>
          <year>2005</year>
          <volume>103</volume>
          <fpage>2344</fpage>
          <lpage>2348</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.21033</pub-id>
          <pub-id pub-id-type="pmid">15844174</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR4">
        <label>4.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Lee</surname>
              <given-names>YJ</given-names>
            </name>
            <name>
              <surname>Choi</surname>
              <given-names>HJ</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>SK</given-names>
            </name>
            <name>
              <surname>Chang</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Moon</surname>
              <given-names>JW</given-names>
            </name>
            <name>
              <surname>Park</surname>
              <given-names>IK</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>JH</given-names>
            </name>
            <name>
              <surname>Cho</surname>
              <given-names>BC</given-names>
            </name>
          </person-group>
          <article-title>Frequent central nervous system failure after clinical benefit with epidermal growth factor receptor tyrosine kinase inhibitors in Korean patients with nonsmall-cell lung cancer</article-title>
          <source>Cancer</source>
          <year>2010</year>
          <volume>116</volume>
          <fpage>1336</fpage>
          <lpage>1343</lpage>
          <pub-id pub-id-type="doi">10.1002/cncr.24877</pub-id>
          <pub-id pub-id-type="pmid">20066717</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR5">
        <label>5.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Jackman</surname>
              <given-names>DM</given-names>
            </name>
            <name>
              <surname>Holmes</surname>
              <given-names>AJ</given-names>
            </name>
            <name>
              <surname>Lindeman</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Wen</surname>
              <given-names>PY</given-names>
            </name>
            <name>
              <surname>Kesari</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Borras</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Bailey</surname>
              <given-names>C</given-names>
            </name>
            <name>
              <surname>Jong</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>J&#xE4;nne</surname>
              <given-names>PA</given-names>
            </name>
            <name>
              <surname>Johnson</surname>
              <given-names>BE</given-names>
            </name>
          </person-group>
          <article-title>Response and resistance in a non-small-cell lung cancer patient with an epidermal growth factor receptor mutation and leptomeningeal metastases treated with high-dose gefitinib</article-title>
          <source>J Clin Oncol</source>
          <year>2006</year>
          <volume>24</volume>
          <fpage>4517</fpage>
          <lpage>4520</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2006.06.6126</pub-id>
          <pub-id pub-id-type="pmid">16983123</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR6">
        <label>6.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Katayama</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Shimizu</surname>
              <given-names>J</given-names>
            </name>
            <name>
              <surname>Suda</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Onozato</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fukui</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Ito</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Hatooka</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Sueda</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Hida</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Yatabe</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Mitsudomi</surname>
              <given-names>T</given-names>
            </name>
          </person-group>
          <article-title>Efficacy of erlotinib for brain and leptomeningeal metastases in patients with lung adenocarcinoma who showed initial good response to gefitinib</article-title>
          <source>J Thorac Oncol</source>
          <year>2009</year>
          <volume>4</volume>
          <fpage>1415</fpage>
          <lpage>1419</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181b62572</pub-id>
          <pub-id pub-id-type="pmid">19692934</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR7">
        <label>7.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Dhruva</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Socinski</surname>
              <given-names>MA</given-names>
            </name>
          </person-group>
          <article-title>Carcinomatous meningitis in non-small-cell lung cancer: response to high-dose erlotinib</article-title>
          <source>J Clin Oncol</source>
          <year>2009</year>
          <volume>27</volume>
          <fpage>31</fpage>
          <lpage>32</lpage>
          <pub-id pub-id-type="doi">10.1200/JCO.2008.21.0963</pub-id>
          <pub-id pub-id-type="pmid">19047280</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR8">
        <label>8.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Clarke</surname>
              <given-names>JL</given-names>
            </name>
            <name>
              <surname>Pao</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Wu</surname>
              <given-names>N</given-names>
            </name>
            <name>
              <surname>Miller</surname>
              <given-names>VA</given-names>
            </name>
            <name>
              <surname>Lassman</surname>
              <given-names>AB</given-names>
            </name>
          </person-group>
          <article-title>High dose weekly erlotinib achieves therapeutic concentrations in CSF and is effective in leptomeningeal metastases from epidermal growth factor receptor mutant lung cancer</article-title>
          <source>J Neurooncol</source>
          <year>2010</year>
          <volume>99</volume>
          <fpage>283</fpage>
          <lpage>286</lpage>
          <pub-id pub-id-type="doi">10.1007/s11060-010-0128-6</pub-id>
          <pub-id pub-id-type="pmid">20146086</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR9">
        <label>9.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Hata</surname>
              <given-names>A</given-names>
            </name>
            <name>
              <surname>Kaji</surname>
              <given-names>R</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Katakami</surname>
              <given-names>N</given-names>
            </name>
          </person-group>
          <article-title>High-dose erlotinib for refractory brain metastases in a patient with relapsed non-small cell lung cancer</article-title>
          <source>J Thorac Oncol</source>
          <year>2011</year>
          <volume>6</volume>
          <fpage>653</fpage>
          <lpage>654</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181d899bb</pub-id>
          <pub-id pub-id-type="pmid">21317753</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR10">
        <label>10.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Togashi</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Masago</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Fukudo</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Terada</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Fujita</surname>
              <given-names>S</given-names>
            </name>
            <name>
              <surname>Irisa</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Sakamori</surname>
              <given-names>Y</given-names>
            </name>
            <name>
              <surname>Kim</surname>
              <given-names>YH</given-names>
            </name>
            <name>
              <surname>Mio</surname>
              <given-names>T</given-names>
            </name>
            <name>
              <surname>Inui</surname>
              <given-names>K</given-names>
            </name>
            <name>
              <surname>Mishima</surname>
              <given-names>M</given-names>
            </name>
          </person-group>
          <article-title>Cerebrospinal fluid concentration of erlotinib and its active metabolite OSI-420 in patients with central nervous system metastases of non-small cell lung cancer</article-title>
          <source>J Thorac Oncol</source>
          <year>2010</year>
          <volume>5</volume>
          <fpage>950</fpage>
          <lpage>955</lpage>
          <pub-id pub-id-type="doi">10.1097/JTO.0b013e3181dab0dd</pub-id>
          <pub-id pub-id-type="pmid">20479691</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR11">
        <label>11.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Zhang</surname>
              <given-names>W</given-names>
            </name>
            <name>
              <surname>Siu</surname>
              <given-names>LL</given-names>
            </name>
            <name>
              <surname>Moore</surname>
              <given-names>MJ</given-names>
            </name>
            <name>
              <surname>Chen</surname>
              <given-names>EX</given-names>
            </name>
          </person-group>
          <article-title>Simultaneous determination of OSI-774 and its major metabolite OSI-420 in human plasma by using HPLC with UV detection</article-title>
          <source>J Chromatogr B Analyt Technol Biomed Life Sci</source>
          <year>2005</year>
          <volume>814</volume>
          <fpage>143</fpage>
          <lpage>147</lpage>
          <pub-id pub-id-type="doi">10.1016/j.jchromb.2004.10.016</pub-id>
          <pub-id pub-id-type="pmid">15607718</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR12">
        <label>12.</label>
        <mixed-citation publication-type="other">Masuda T, Hattori N, Hamada A, Iwamoto H, Ohshimo S, Kanehara M, Ishikawa N, Fujitaka K, Haruta Y, Murai H, Kohno N (2011) Erlotinib efficacy and cerebrospinal fluid concentration in patients with lung adenocarcinoma developing leptomeningeal metastases during gefitinib therapy. Cancer Chemother Pharmacol 67:1465&#x2013;1469</mixed-citation>
      </ref>
      <ref id="CR13">
        <label>13.</label>
        <mixed-citation publication-type="journal">
          <person-group person-group-type="author">
            <name>
              <surname>Elmeliegy</surname>
              <given-names>MA</given-names>
            </name>
            <name>
              <surname>Carcaboso</surname>
              <given-names>AM</given-names>
            </name>
            <name>
              <surname>Tagen</surname>
              <given-names>M</given-names>
            </name>
            <name>
              <surname>Bai</surname>
              <given-names>F</given-names>
            </name>
            <name>
              <surname>Stewart</surname>
              <given-names>CF</given-names>
            </name>
          </person-group>
          <article-title>Role of ATP-binding cassette and solute carrier transporters in erlotinib CNS penetration and intracellular accumulation</article-title>
          <source>Clin Cancer Res</source>
          <year>2011</year>
          <volume>17</volume>
          <fpage>89</fpage>
          <lpage>99</lpage>
          <pub-id pub-id-type="doi">10.1158/1078-0432.CCR-10-1934</pub-id>
          <pub-id pub-id-type="pmid">21088257</pub-id>
        </mixed-citation>
      </ref>
      <ref id="CR14">
        <label>14.</label>
        <mixed-citation publication-type="other">de Vries NA, Buckle T, Zhao J, Beijnen JH, Schellens JH, van Tellingen O (2010) Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP. Invest New Drugs [Epub ahead of print]</mixed-citation>
      </ref>
    </ref-list>
  </back>
</article>
</pmc-articleset>
